Integral Molecular Achieves ISO 9001 Certification for its Membrane Proteome Array Service
2024-03-27
ISO 9001 certification validates Integral Molecular's quality processes for its Membrane Proteome Array, reflecting the company's commitment to quality.
PHILADELPHIA, March 27, 2024 /PRNewswire/ -- Integral Molecular, a leader in antibody discovery and characterization, proudly announces the achievement of IS0 9001 certification for the quality systems and processes used in its Membrane Proteome Array™ (MPA) specificity testing services. This platform is a vital tool for biotechnology and pharmaceutical companies to assess the safety and off-target reactivity of therapeutic antibodies and other biologics.
Despite their reputation for 'exquisite specificity', antibodies and antibody-based therapies, such as CAR-T cells, frequently demonstrate unexpected off-target binding. The MPA utilizes its collection of over 6,000 native-conformation membrane proteins that encompass nearly the entire human membrane proteome to de-risk therapeutics and reveal unintended off-target liabilities early in drug development.
Learn more about the
Membrane Proteome Array™
ISO 9001 is a globally recognized standard for quality management systems (QMS) that encompass process controls, comprehensive documentation, plans for corrective action, and continuous improvement.
"Integral Molecular has maintained a culture of commitment to delivering exceptional quality products and services for over 20 years. As the industry increasingly relies on MPA specificity profiling to support drug safety, we are delighted to receive ISO 9001 Certification to reinforce our commitment to quality for our customers."
-Rachel Fong, Director of Sales and Alliances, Integral Molecular
With the ability to pinpoint the identity of unanticipated protein interactions that could pose safety consequences, the MPA was accepted by the FDA to participate in the agency's ISTAND program to qualify new drug development tools for IND, NDA, or BLA applications. The MPA qualification plan was submitted to the FDA in 2023 and is currently under review.
About Integral Molecular
Integral Molecular (integralmolecular.com) is the industry leader in creating and commercializing transformative technologies that advance the discovery of therapeutics against difficult protein targets. With 20+ years of experience focused on membrane proteins, viruses, and antibodies, Integral Molecular's technologies have been integrated into the drug discovery pipelines of over 600 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, autoimmune disorders, and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue viruses.
Follow Integral Molecular on LinkedIn
Press Contact:
Soma Banik, PhD, Director of Public Relations
215-966-6061
[email protected]
www.integralmolecular.com
SOURCE Integral Molecular
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-药物
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。